Daiichi Sankyo Co., Ltd. is a leading pharmaceutical company based in Japan, specializing in antibody drug conjugates (ADCs). With a low ESG risk rating score of 19.8, Daiichi Sankyo has been a key player in the healthcare industry since the merger of Daiichi Pharmaceuticals and Sankyo in 2005. Their primary growth drivers include key ADCs such as Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu, for example, has received approvals for various types of cancer, including HER2-positive breast, stomach, and non-small cell lung cancers. As Daiichi Sankyo expands its global presence, the company's revenue from Japan is expected to decrease over time.